Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Systemic lupus erythematosus
•
Complement system
•
Allergy & Immunology
•
Urticaria/Angioedema
How do you interpret high C1q binding assay with otherwise normal C1q, C3, C4, CH50 in a patient with recurrent urticaria with positive ANA at high titer 1:1280, negative dsDNA, RNP, SM, normal CBC, CMP, UA, and UPCR.
Related Questions
How have you utilized commercial lab "SLE Monitoring Profiles" that include C3a and C4a components?
How often do you rely on using the C1 inhibitor functional assay versus quantitative level alone to diagnosis HAE?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
Is there a role for voclosporin in non-renal lupus?
Would you consider belimumab for an SLE patient who has generalized hair thinning, leukopenia (WBC <3), low C3, and markedly positive anti-dsDNA who is otherwise asymptomatic?
Would you continue belimumab in high risk lupus patients with overlapping scleroderma features with ILD who become pregnant and who are already on HCQ and azathioprine?
How would you approach the work up of SLE in a patient over 80 years old?
Do you perform genetic testing when patients have persistent hypogammaglobulinemia after rituximab therapy?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Would you accept the diagnosis of SLE on the basis of an AVISE CTD panel where the results just showed a positive EC4d or BC4d, positive ANA>1/80 + one clinical criteria such as multiple tender joints but did otherwise not fulfill criteria for SLE?
